| PACKAGING TYPE: | Alu-alu |
| COMPOSITION: | Each Film Coadted Bilayered Tablet Contains : Dapagliflozin Propanediol Monohydrate Usp Eq To Dapagliflozin 5mg , Vildagliptin Ip (sustained Release ) 100mg |
| FORMULATION: | Tablets |
| Description: | VIDASAFE D 100/5 Tablet is a combination oral antidiabetic medication containing Vildagliptin 100mg and Dapagliflozin 5mg. This dual-action therapy is designed for type 2 diabetes mellitus to help control blood sugar levels more effectively. Vildagliptin is a DPP-4 inhibitor that increases incretin hormones, enhancing insulin release and reducing glucagon secretion. Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion and lowering blood sugar. This combination offers synergistic glucose-lowering effects, improving glycemic control with a lower risk of hypoglycemia. |
| Side Effects: | Common side effects may include: Urinary tract infections Increased urination Headache or dizziness Nausea or mild gastrointestinal discomfort Serious (rare) side effects: Severe allergic reactions Pancreatitis (abdominal pain, nausea, vomiting) Kidney function abnormalities Low blood pressure or dehydration |
| How to Use: | Take the tablet as prescribed by your doctor Usually administered once daily, with or without food Swallow whole with water Maintain regular blood sugar monitoring and follow prescribed dosage |
| Precaution: | Use cautiously in patients with kidney or liver impairment Stay hydrated while taking this medication Inform your doctor about other medications and medical conditions Not recommended during pregnancy or breastfeeding unless advised Monitor blood sugar and kidney function regularly |
| Product Benefits: | Effective dual-action control of blood sugar in type 2 diabetes Enhances insulin secretion and reduces glucagon levels (Vildagliptin) Increases urinary glucose excretion (Dapagliflozin) Can be used in patients inadequately controlled on monotherapy Ma |
Frequently Asked Questions
It is used for better blood sugar control in type 2 diabetes by combining the effects of Vildagliptin and Dapagliflozin.
Vildagliptin increases insulin secretion and reduces glucagon, while Dapagliflozin promotes urinary glucose excretion to lower blood sugar.
Yes, Dapagliflozin can aid in mild weight reduction alongside improved glycemic control.











